| abstract |
The present disclosure relates to TSLP binding proteins, such as anti-TSLP single variable domains, polynucleotides encoding such TSLP binding proteins, pharmaceutical compositions and kits comprising said TSLP binding proteins and methods of manufacture. The present invention also concerns the use of such TSLP binding proteins in the treatment of diseases associated TSLP signalling, such as asthma. |